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Aging is the primary risk factor for cognitive decline,
an emerging health threat to aging societies world-
wide. Whether anti-aging factors such as klotho
can counteract cognitive decline is unknown. We
show that a lifespan-extending variant of the human
KLOTHO gene, KL-VS, is associated with enhanced
cognition in heterozygous carriers. Because this
allele increased klotho levels in serum, we analyzed
transgenicmicewith systemic overexpression of klo-
tho. They performed better than controls in multiple
tests of learning and memory. Elevating klotho in
mice also enhanced long-term potentiation, a form
of synaptic plasticity, and enriched synaptic
GluN2B, an N-methyl-D-aspartate receptor (NMDAR)
subunit with key functions in learning and memory.
Blockade of GluN2B abolished klotho-mediated
effects. Surprisingly, klotho effects were evident
also in young mice and did not correlate with age in
humans, suggesting independence from the aging
process. Augmenting klotho or its effects may
enhance cognition and counteract cognitive deficits
at different life stages.
INTRODUCTION
The world’s population is aging rapidly, and preserving brain
health has emerged as a major biomedical challenge. Without
novel interventions, over 80 million people worldwide will suffer
frommemory problems resulting from aging and age-related dis-
ease by 2040 (Prince et al., 2013). Because aging, a processCamenable to change (Guarente andKenyon, 2000), is the primary
risk factor for failing cognition, regulators of aging might be
harnessed for the treatment and prevention of cognitive decline.
Like aging, cognition is modifiable. Learning and memory
depend on networks spanning different brain regions, including
the hippocampus and cortex (Ranganath and Ritchey, 2012;
Wang and Morris, 2010), and involve coordinated activities of
N-methyl-D-aspartate (NMDA) (Gladding and Raymond, 2011;
Lee and Silva, 2009)- and a-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) (Kerchner and Nicoll, 2008; Kessels
and Malinow, 2009)-type glutamate receptors (NMDARs and
AMPARs). Importantly, NMDAR- and AMPAR-mediated func-
tions are disrupted by aging (Henley and Wilkinson, 2013;
Magnusson et al., 2010) and age-related neurodegenerative
disease (Chang et al., 2012; Li et al., 2011).
Whether factors that prolong life can also prevent, delay, or
counteract neural dysfunction associated with aging and dis-
ease is a critical question with therapeutic implications. Klotho
is an aging regulator that, when overexpressed, extends lifespan
(Kurosu et al., 2005) and, when disrupted, accelerates aging
phenotypes (Kuro-o et al., 1997). Higher klotho levels increase
lifespan in mice (Kurosu et al., 2005) and nematodes (Chaˆteau
et al., 2010). In humans, a single allele of the KL-VS variant of
the KLOTHO gene, which increases secreted klotho (Arking
et al., 2002) andmore strongly activates FGF23 signaling (Tucker
Zhou et al., 2013) in cell culture, promotes longevity (Arking et al.,
2002, 2005; Invidia et al., 2010) and diminishes age-related heart
disease (Arking et al., 2005).
Klotho is a pleiotropic protein. Its transmembrane form (Shir-
aki-Iida et al., 1998) can be released by sheddases (Chen
et al., 2007) and circulate throughout the body and brain (Imura
et al., 2004; Kurosu et al., 2005). Klotho suppresses insulin (Kur-
osu et al., 2005) and wnt (Liu et al., 2007) signaling, regulates ion
channel clustering (Chang et al., 2005) and transport (Imura et al.,ell Reports 7, 1065–1076, May 22, 2014 ª2014 The Authors 1065
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Figure 1. The KL-VS Allele Is Associated with Better Cognitive Per-
formance in Three Independent Aging Populations without Demen-
tia and in a Meta-Analysis of the Populations
Neuropsychological scores from tests spanning multiple cognitive domains
(Table S4; Figure S1). Global composite Z-scores of 718 aging individuals (52–
85 years of age) that were non-carriers (black; n = 530) or carriers (purple; n =
188) of a single KL-VS allele were obtained from three independent cohorts
without cognitive impairments. In each cohort, an individual composite score
was standardized and scaled to reflect performance as a measure of the
number of SDs from the global average of that cohort (global composite Z-
score). Higher scores indicate better cognitive performance. (A–C) Global
composite Z-scores in (A) cohort 1 (179 non-carriers, 41 carriers), (B) cohort 2
(331 non-carriers, 135 carriers), (C) cohort 3 (20 non-carriers, 12 carriers), and
(D) meta-analysis of the cohorts. All subjects had an MMSE score of 28 or
greater and no dementia. Data were analyzed by linear models, accounting for
effects of age, sex, and education and testing for effects due to KL-VS ge-
notype. APOE ε4 carrier status had no significant effects (Tables S5 and S6).
p = 0.06, *p < 0.05, **p < 0.01, ***p < 0.001 versus non-carrier (linear re-
gression t test). Data are mean ± SEM. See also Tables S2–S6 and Figure S1.2007), and promotes FGF23 function (Urakawa et al., 2006).
Although it regulates aging-dependent pathways (Kurosu et al.,
2005; Liu et al., 2007), klotho also supports physiologic functions
that are aging independent (Chang et al., 2005; Razzaque, 2009).
In mice, genetic klotho reduction during embryogenesis
results in early postnatal death, hypomyelination (Chen et al.,
2013), synaptic attrition (Shiozaki et al., 2008), and cognitive
impairment (Nagai et al., 2003), suggesting that klotho is required
for brain maturation. Because klotho circulates in serum and ce-
rebrospinal fluid throughout life (Imura et al., 2004, 2007), and
declines with aging (Duce et al., 2008; Semba et al., 2011,1066 Cell Reports 7, 1065–1076, May 22, 2014 ª2014 The Authors2014), in parallel to the emergence of cognitive deficits, it is
possible that klotho also fulfills important functions in the CNS
at later life stages.
We therefore investigated whether klotho can impact physio-
logical brain function and, more specifically, whether it can
prevent or counteract cognitive decline in human aging. We
demonstrate that the lifespan-extending variant of the KLOTHO
gene, KL-VS, is associated with increased klotho levels in serum
and enhanced cognition in aging people heterozygous for the
allele in three cohorts and across multiple ages. We also
analyzed transgenic mice with moderate systemic overexpres-
sion of klotho. Independent of age, these mice performed better
in multiple tests of learning and memory than controls. Further
investigation of potential underlying mechanisms revealed unex-
pected effects of klotho elevation on the functions of synapses
and glutamate receptors.
RESULTS
KL-VS Genetic Variant of KLOTHO Is Associated with
Enhanced Cognition in Three Independent Human
Cohorts and in a Meta-Analysis
Wefirst examinedwhether the KL-VS genetic variant ofKLOTHO
predicts healthy brain aging in humans in three independent
populations, including the Hillblom Aging Study (cohort 1), the
Memory and Aging Project (cohort 2), and the Normal Aging
Cohort (cohort 3) (Table S1). Collectively, the cohorts comprised
718 individuals (52–85 years of age), primarily Caucasian,
without dementia or cognitive complaints, and with a Mini-
Mental State Exam (MMSE) score of 28 or greater (see Tables
S2 and S3 for inclusion criteria and demographics). Twenty-six
percent of individuals were heterozygous for the KL-VS allele,
slightly above typical frequencies of 20%–25% (Arking et al.,
2002). Three percent were homozygous for KL-VS, a rare
genotype that for unknown reasons is associated with
decreased lifespan and detrimental effects (Arking et al., 2002,
2005; Deary et al., 2005); they were excluded from the study.
In each cohort, cognitive abilities of heterozygous KL-VS
carriers and non-carriers were analyzed usingmultiple neuropsy-
chological tests (Table S4; Figure S1) and compiled into global
composite Z-scores (Figures 1A–1C and S1). The scores repre-
sent a broad measure of cognition, including domains vulnerable
to aging (Drag and Bieliauskas, 2010), and reflect the number of
SDs from the global average. We used linear statistical models
including KL-VS carrier status (zero or one allele), age, sex, and
education, with or without APOE ε4, as predictors for perfor-
mance (Table S5). APOE ε4, the main genetic risk factor for
Alzheimer’s disease (AD) (Verghese et al., 2011), did not con-
tribute significant variance (Table S5), and including ‘‘cohort’’ as
a covariate inmeta-analysis did not alter results (data not shown).
KL-VScarriers scoredhigher than non-carriers in eachcohort and
in meta-analysis of all cohorts (Figures 1A–1D; Table S5).
KL-VS Is Associated with Better Cognition Independent
of Age, Sex, and APOE ε4 Allele Status
Meta-analysis showed that advancing age, male sex, and lower
education decreased cognitive scores; KL-VS heterozygosity
increased scores despite these effects (Table S5). Baseline
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Figure 2. KL-VS-Associated Cognitive Enhancement Is Independent
of Age
(A–C) Global composite Z-scores decreased as a function of age in non-
carriers (empty squares) and carriers (purple squares) of the KL-VS allele in (A)
cohort 1, (B) cohort 2, and (C) cohort 3.
(D) In meta-analysis of all cohorts, KL-VS-associated cognitive enhancement
tended to decrease with advancing age (KL-VS:age interaction, p = 0.10 by
ANOVA). Data were analyzed by linear models, accounting for effects of age,
sex, and education and testing for effects due to an age by KL-VS interaction.
APOE ε4 carrier status had no significant effects on these measures.
Data are mean ± SEM.
See also Tables S5 and S6.cognition was not affected by APOE ε4, consistent with previous
findings (Yaffe et al., 1997), though detrimental effects of APOE
ε4 on cognitive aging might be revealed by longitudinal analysis
(Deary et al., 2002; Yaffe et al., 1997). KL-VS did not differentially
affect cognition by sex (Table S6), but there was a trend (Table
S6) for its positive impact to decrease with advancing age (Fig-
ures 2A–2D).
KL-VS Increases Klotho Levels in Sera of Humans
Based on these findings, we concluded that KL-VS enhances
baseline cognition and hypothesized that it does so, in part, by
increasing klotho levels or activity. To begin to test this, we
measured fasting, morning levels of klotho in serum by ELISA
in individuals from cohort 1 with no or one KL-VS allele. Consis-
tent with findings in cell culture (Arking et al., 2002), the KL-VS
variant significantly increased levels of secreted klotho in the
serum (Figure 3A; Table S7).
Elevation of Klotho Promotes Longevity and Enhances
Cognition in Mice in an Age-Independent Manner
To test whether systemic increases in klotho levels enhance
cognition, we analyzed heterozygous klotho (KL) transgenic
mice that overexpress mouse klotho in plasma (Kurosu et al.,
2005) and throughout the body and brain (Kuro-o et al., 1997),
including the hippocampus (Figure 3B), which is critical toClearning and memory. Klotho overexpression improved survival
in mice, independent of age or time by proportional hazard
analysis (Figure 3C). Similar to our human findings, these data
suggest that klotho can engagemechanisms that do not depend
on aging per se.
We tested spatial learning and memory in 10- to 12-month-old
(‘‘middle-aged’’) mice in the Morris water maze. KL mice
performed better than nontransgenic (NTG) controls (Figure 3D).
After hidden-platform training, the platform was removed, and
spatial memory retention was assessed in a probe trial. KL
mice reached the original platform location 2.5 times faster
than NTG mice (Figure 3E). Klotho elevation also improved
spatial learning and memory in 4- to 7-month-old (‘‘young’’)
mice (Figures 3F and 3G). Effects were independent of sex (Table
S8). Of note, KL and NTG mice swam at equal speeds (Figures
S2A and S2B) and located a cued platform equally well (Figures
S2C and S2D). Thus, elevation of klotho enhances spatial
learning and memory independent of sex and across different
age groups. Because the effect of klotho on youngmice was sur-
prising and such mice are readily available and most suitable for
electrophysiological analysis, we focused subsequent studies
on this age group.
Klotho Elevation Improves Working and Fear Memory
without Altering Other Behaviors in Young Mice
We tested whether elevation of klotho in mice enhances cogni-
tion in youngmice (3–4 and 4–7 months of age) in other cognitive
tasks. In the Y maze, KL mice showed more alternations than
NTG controls (Figure 4A), an indication of superior workingmem-
ory. In a fear-conditioning paradigm, KL mice showed better
contextual memory than NTG mice (Figure 4B) but similar cued
recall (Figures S3A and S3B). In contrast, klotho elevation did
not affect exploratory and anxiety-related behaviors in the
open field (Figure 4C) or elevated plus maze (Figure 4D). Thus,
elevation of klotho enhances learning and memory in a range
of tasks without altering other behaviors.
Klotho Elevation Increases Synaptic Levels of the
GluN2B Subunit of NMDARs in Mouse Hippocampus and
Cortex
To further explore themechanism underlying beneficial effects of
klotho on cognition, we turned our attention to NMDARs and
AMPARs, whose functions are essential for learning andmemory
(Anggono and Huganir, 2012; Nakazawa et al., 2004). An initial
screen of their subunit expression in hippocampus revealed
that klotho elevation specifically increased total protein levels
of the NMDAR subunit GluN2B (Figures S4A–S4E), without
altering its mRNA (Figure S4F). Interestingly, transgenic overex-
pression of GluN2B in mice (Cao et al., 2007; Tang et al., 1999)
and rats (Wang et al., 2009) enhances cognition, whereas
dysfunction of this subunit in humans and mice contributes to
cognitive decline in aging (Piggott et al., 1992; Zhao et al.,
2009) and AD (Ittner et al., 2010; Li et al., 2011; Sze et al.,
2001). In light of these findings and because the enhancement
of learning and memory in KL mice resembled that in GluN2B-
overexpressing mice, we investigated whether klotho modulates
the GluN2B protein at synapses in the hippocampus and frontal
cortex, regions directly involved in cognitive functions. Klothoell Reports 7, 1065–1076, May 22, 2014 ª2014 The Authors 1067
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Figure 3. Elevation of Systemic Klotho Levels Occurs in Human KL-
VS Carriers and Enhances Mouse Survival, Learning, and Memory
Independent of Age
(A) Fasting morning serum klotho levels in individuals from cohort 1 (55–85
years of age) that were non-carriers (n = 118) or carriers (n = 38) of a single KL-
VS allele. Data were analyzed by a linear model, accounting for effects of age,
sex, and education and testing for effects due to KL-VS genotype. APOE ε4
carrier status had no effect (Table S7).
(B) Hippocampal levels of klotho in NTG and KL mice (n = 13–14 mice per
genotype, age 3months). Representative western blots for klotho and actin are
shown above; images for each protein were from the same gel.
(C) Kaplan-Meier curves show increased survival of heterozygous KL mice
from line 46 (Kuro-o et al., 1997; Kurosu et al., 2005) compared to NTG
littermates (n = 22–29 mice per group; p < 0.01 by log rank test). Proportional
hazard testing revealed that the KL effect was independent of age (p = 0.76).
(D and E) KL and NTG mice (n = 8–9 mice per genotype) were tested in the
Morris water maze at 10–12 months of age.
(D) Spatial learning curves (platform hidden) are shown. Data represent the
daily average of total distance traveled to the platform. KL effect, p < 0.05, by
mixed-model ANOVA.
(E) Results of a probe trial (platform removed) 1 hr after completion of hidden-
platform training show latency to reach the original platform location.
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Figure 4. Klotho Elevation Also Improves Working and Context
Memory without Altering Other Behaviors in Young Mice
(A) Percent alternations among arms by 3- to 4-month-old mice during
exploration of a Y maze (n = 8–10 mice per genotype).
(B) Percent time 6-month-old mice spent freezing at baseline and 24 hr after
context training in a fear-conditioning task (n = 6–7 male mice per genotype).
(C) Movements during exploration of an open field (n = 13–14 mice per ge-
notype; p = 0.30 by two-tailed t test).
(D) Percent time spent exploring the open arms of an elevated plus maze (n =
14–15 mice per genotype; p = 0.60 by two-tailed t test).
*p < 0.05, ***p < 0.001 versus chance or as indicated by bracket (t test). Data
are mean ± SEM. See also Figure S3.
1068 Cell Reports 7, 1065–1076, May 22, 2014 ª2014 The Authorselevation nearly doubled GluN2B, but not GluN2A or GluN2C,
levels in postsynaptic density (PSD) fractions isolated from the
mouse hippocampus (Figures 5A–5C). It did so without altering
presynaptic (synaptophysin) and postsynaptic (PSD-95) markers
in membrane fractions (Figures 5A, 5D, and 5E). We also
found klotho-mediated increases in GluN2B in PSD-enriched
fractions from the frontal cortex (Figures 5F and 5G).
Collectively, these data suggest that klotho elevates synaptic
GluN2B in a subunit-specificmanner through posttranscriptional
mechanisms.(F and G) An independent cohort of mice (n = 17–19 mice per genotype) was
tested in the water maze at 4–7 months of age.
(F) Spatial learning curves (platform hidden). KL effect, p < 0.05 by mixed-
model ANOVA.
(G) Probe trial results.
*p < 0.05, **p < 0.01, ***p < 0.001 (t test). Data are mean ± SEM. See also
Tables S7 and S8 and Figure S2.
A B
C D E
F G
Figure 5. Klotho Overexpression Enhances
Synaptic GluN2B Levels in the Hippocam-
pus and Cortex
(A–G) Synaptic membrane Fraction 1 (PSD en-
riched) and Fraction 2 (non-PSD enriched) isolated
from hippocampus or cortex of NTG and KL mice
(n = 15–18 mice per genotype, age 3–4 months).
(A) Representative western blots of hippocampal
fractions. Klotho overexp., Klotho overexpression.
(B–E) Quantitation of (B) GluN2A, GluN2B, and
GluN2C levels in hippocampal Fraction 1, (C)
GluN2B in hippocampal Fractions 1 (left) and 2
(right), (D) PSD-95 and GluN2B, and (E) synapto-
physin levels.
(F) Representative western blots of cortical frac-
tions isolated from frontal, motor, and somato-
sensory regions (bregma, 0–3.5 mm).
(G) Quantitation of GluN2B levels in cortical Frac-
tions 1 (left) and 2 (right). For each fraction, protein
levels are relative to NTG levels, arbitrarily defined
as 1.0.
*p < 0.05 versus NTG (t test); n.s., not significant.
Data are mean ± SEM. See also Figure S4.Klotho Elevation Increases NMDAR-Dependent Gene
Expression and Synaptic Plasticity
We next analyzed effects of klotho elevation on NMDAR-depen-
dent gene expression and synaptic plasticity. We first examined
Fos, an immediate early gene that is involved in memory consol-
idation (Kubik et al., 2007) and increased by NMDAR activation
(Badinget al., 1993).WemeasuredFOS-positive cells in thegran-
ular layer of the hippocampal dentate gyrus in 3- to 4-month-old
KL and NTGmice after hidden-platform training and a probe trial
in the water maze, tasks that engage the dentate gyrus and other
regions of the hippocampus and cortex (Wang andMorris, 2010).
Consistent with findings in mice at 10–12 and 4–7 months of age
(Figures 3D–3G), KLmice also showed better learning andmem-
ory in thewatermaze at 3–4months (data not shown). In the sameCell Reports 7, 1065–107cohort, FOS expression was more promi-
nent in KL mice than NTG controls
following the probe trial (Figures 6A and
6B), indicating that enhanced cognition
in KLmice was associated with increased
NMDAR-dependent gene expression.
NMDAR activation is also critical for
long-term potentiation (LTP), a form of
synaptic plasticity thought to underlie
learning and memory (Morris et al.,
1986; Nakazawa et al., 2004). To assess
whether klotho enhances synaptic plas-
ticity, we measured LTP in acute hippo-
campal slices at the medial perforant
path to granule cell synapse, which is
mostly mediated by NMDARs (Nguyen
and Kandel, 1996). Elevation of klotho
enhanced hippocampal LTP (Figure 6C)
without changing AMPAR-mediated
basal synaptic strength (Figures 6D and
S5), as determined by field excitatorypostsynaptic potential (fEPSP) and whole-cell excitatory post-
synaptic current (EPSC) recordings.
Klotho Elevation Increases the GluN2B Portion of
NMDAR Currents
We observed that klotho-mediated enrichment of synaptic
GluN2B positively correlated with GluN1 levels (Figures S6A and
S6B), suggesting an increase in functional GluN2B-containing
NMDARs. To assess whether overexpression of klotho increases
NMDAR currents, we measured the amplitude and kinetics of
synaptic NMDAR-mediated currents by whole-cell patch-clamp
recordings from dentate granule cells following perforant path
stimulation. Because AMPAR-mediated synaptic transmission
did not differ between NTG and KL slices (Figures 6D and S5),6, May 22, 2014 ª2014 The Authors 1069
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Figure 6. Klotho Overexpression Enhances
NMDAR-, but Not AMPAR-, Dependent
Functions
(A and B) FOS expression in the dentate gyrus of
NTG and KL mice immediately following a probe
trial in the water maze.
(A) Staining with antibodies to FOS revealed more
immunoreactive granule cells in the dentate gyrus
of KL (bottom) than NTG (top) mice. Scale bar,
100 mm.
(B) Quantitation of FOS-positive granule cells (n = 7
mice per genotype, age 3–4 months). The mean
level in NTG controls was arbitrarily defined as 1.0.
(C) fEPSP recordings from acute hippocampal
slices of 3.5- to 4.5-month-old NTG and KL mice.
LTP induction and decay in the dentate gyrus were
monitored for 45–50 min following theta burst
stimulation of the medial perforant pathway. KL
versus NTG genotype by time effect, p < 0.01 by
mixed-model ANOVA. Four slices from four NTG
mice and eight slices from six KL mice were
analyzed.
(D) AMPAR-mediated basal synaptic transmission
in acute hippocampal slices of 3.5- to 4.5-month-
old mice at the medial perforant path to dentate
granule cell synapse. Five slices from three NTG
mice and nine slices from five KL mice were
analyzed.
(E–G) Isolated NMDAR and AMPAR EPSCs
measured by whole-cell patch-clamp recordings
from dentate granule cells in acute hippocampal
slices of 3- to 4-month-old mice.
(E) Representative traces of evoked EPSCs at +40 or 70 mV. NMDAR-mediated EPSCs were quantitated between 80 and 100 ms after stimulation (blue
shading) in the top traces and AMPAR-mediated EPSCs at the nadir of the bottom traces. Scales, 100 pA and 50 ms.
(F) Quantitation of AMPAR/NMDAR EPSC ratios. Ten slices from three NTG mice and ten slices from three KL mice were analyzed. p = 0.32 (t test).
(G) Decay constant (t) of isolated NMDAR EPSCs in the presence of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) (10 mM). Seven
slices from three NTG mice and five slices from three KL mice were analyzed.
*p < 0.05, **p < 0.01 (t test). Data are mean ± SEM. See also Figure S5.the amplitudes of NMDAR currents were normalized to AMPAR
currents, revealing similar amplitudes in NTG and KL slices (Fig-
ures 6Eand6F).However, NMDARcurrents decayedmoreslowly
in KL slices thanNTGslices, reflectedby an increaseddecay con-
stant (Figure 6G). Because NMDARs containing GluN2B deacti-
vate slower than those containing GluN2A (Wang et al., 2008),
the increased decay time of currents in KL slices suggests that
GluN2B-containing NMDARs contributed more to currents in KL
slices than inNTGslices. Consistentwith this interpretation, treat-
ment of slices with the GluN2B-specific antagonist ifenprodil
(Mony et al., 2009) reduced NMDAR current amplitudes (Figures
7A and 7B) and decay constants (Figures 7C and 7D) more in
KL slices than in NTG slices. Thus, klotho elevation probably in-
creases the GluN2B component of synaptic NMDAR activity.
Acute Inhibition of GluN2B Blocks Klotho-Mediated
Enhancement of Learning and Memory
We tested whether blocking GluN2B-containing NMDARs
modulates effects of klotho elevation on context and working
memory. We specifically tested if acute, transient, and broad
blockade of GluN2B affects klotho-mediated enhancement of
cognition without disrupting baseline cognitive functions. To
this end, we used low doses of pharmacological GluN2B antag-1070 Cell Reports 7, 1065–1076, May 22, 2014 ª2014 The Authorsonists that minimally affect NTG mice (Mathur et al., 2009;
Sotres-Bayon et al., 2007). Youngmicewere injected intraperito-
neally (i.p.) with ifenprodil (5 mg/kg) or vehicle before training in
fear conditioning and then tested 1 day later. Untreated KL
mice showed better hippocampus-dependent contextual fear
memory than untreated NTG mice (Figure 7E), consistent with
their superior performance in other cognitive tasks (Figures
3D–3G, 4A, and 4B), enhanced hippocampal LTP (Figure 6C),
and increased GluN2B function (Figures 7A and 7B). At the low
dose used, ifenprodil did not affect fear conditioning in NTG con-
trols (Figure 7E), consistent with previous results from Kojima
et al. (2005) and Sotres-Bayon et al. (2007). In KLmice, ifenprodil
blocked enhancement of context learning and memory (Fig-
ure 7E). At a higher dose, and with a lower number of shocks,
ifenprodil suppressed learning and memory also in NTG mice
(Figure S6C).
To assess effects of ifenprodil during another life stage and in
another behavioral task, we injected middle-aged mice i.p. with
ifenprodil or vehicle and tested them in the Y maze, which
engages frontal cortical circuits. Untreated KL mice showed
better working memory than NTGmice, as measured by percent
alternations between maze arms (Figure 7F). In KLmice, ifenpro-
dil blocked the enhancement of working memory (Figure 7F).
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Figure 7. Treatment with GluN2B Selective Antagonists Blocks
Klotho Effects on NMDAR Currents and Cognition
(A and B) Representative traces (A) and quantitation (B) of isolated NMDAR
EPSCs in the presence of NBQX (10 mm) at baseline (black) and following
perfusion with ifenprodil (Ifen; 3 mM) (red) in the same slices. Six slices from
three NTG mice and five slices from three KL mice were analyzed. Two-way
repeated-measures ANOVA: ifenprodil effect, p < 0.0001; ifenprodil by KL
interaction, p < 0.05.
(C) Time course of NMDAR EPSC decay constant following ifenprodil perfu-
sion in each genotype. Mixed-model ANOVA: p < 0.0001 for KL versus NTG
genotype by time effect.
(D) Change in decay constant (t) between 0 and 10 min after initiation of
ifenprodil treatment in NTG and KL slices. Seven slices from three NTG mice
and five slices from three KL mice were analyzed.
(E and F) Mice (n = 8–19 per group) received a single i.p. injection of vehicle ()
or ifenprodil (5 mg/kg) 30min before training in a fear-conditioning paradigm or
testing in the Y maze.
(E) Percent time mice (age 5–7 months) spent freezing at baseline and 24 hr
after context training in a fear-conditioning task. Ifenprodil by KL interaction,
p < 0.05 by two-way ANOVA.
(F) Percent alternations among Y maze arms that mice (age 10–12 months)
showed during 3 min exploration. Ifenprodil by KL interaction, p < 0.09 by
two-way ANOVA.
(G and H) Mice (n = 13–19 per group, age 3–5 months) received a single i.p.
injection of vehicle () or Ro 25 (5 mg/kg) 10 min before testing in Y maze.
(G) Percent alternations among Ymaze arms. Ro 25 by KL interaction, p < 0.05
by two-way ANOVA.
(H) Percent decrease in alternations following Ro 25 treatment in NTG and
KL mice.
CThus, at a low dose, ifenprodil blocked klotho-mediated cogni-
tive enhancement in young and middle-aged mice in two inde-
pendent cognitive measures.
To further test and validate the role of GluN2B in klotho-medi-
ated cognitive enhancement, we used Ro 25-6981 (Ro 25), a
second-generation NDMAR blocker with 3,000-fold specificity
to GluN2B relative to other subunits (Paoletti and Neyton,
2007). Young mice were injected i.p. with a low dose of Ro 25
(5 mg/kg) (Mathur et al., 2009) or vehicle and tested in the Y
maze. As expected, vehicle-treated, but not Ro 25-treated, KL
mice showed better workingmemory than NTG controls (Figures
7G and 7H). Altogether, these results are consistent with the syn-
aptic enrichment of GluN2B in KL mice (Figure 5B) and the
greater susceptibility of KL slices to ifenprodil-induced suppres-
sion of NMDAR currents (Figures 7A–7D).
DISCUSSION
Our genetic and neuropsychological data in humans combined
with molecular, electrophysiological, pharmacological, and
behavioral studies in transgenic mice reveal a role for the life
extension factor klotho in enhancing cognition. In three indepen-
dent human populations, the longevity-promoting KL-VS variant
of the KLOTHO gene was associated with enhanced cognition in
heterozygous individuals across all ages examined. As pre-
dicted, based on cell culture studies by Arking et al. (2002),
KL-VS increased klotho levels in the sera of heterozygous indi-
viduals. In mice, systemic overexpression of klotho improved
learning and memory in multiple cognitive tests, and this effect
was independent of age. Klotho elevation enhanced NMDAR-
related functions, including FOS expression following a learning
andmemory task and LTP in the dentate gyrus. It also resulted in
postsynaptic enrichment of the NMDAR subunit GluN2B in the
hippocampus and cortex, brain regions central to networks sup-
porting cognition. Acute blockade of GluN2B abolished klotho-
mediated effects on hippocampal NMDAR currents and on
learning and memory. Taken together, these data support the
hypothesis that, in addition to extending lifespan, klotho exerts
beneficial effects on cognitive and synaptic functions through
mechanisms that involve regulation of NMDARs and are un-
coupled from aging per se.
Klotho and Better Cognitive Status: Effect Size,
Relevance, and Caveats
Because cognition is a highly valued and central manifestation of
brain function that diminishes with aging and disease, the poten-
tial to enhance it—even slightly—is of great relevance to the hu-
man condition. In human studies, we captured the magnitude of
group differences in cognition between KL-VS carriers and non-
carriers, by calculating an ‘‘effect size’’ with the widely used Co-
hen’s dmethod (Ray and Shadish, 1996) to estimate the biologic
significance of our findings. In studies of human cognition and
behavior, an effect size of 0.25 on a scale of 0–1 is broadly*p < 0.05, **p < 0.01, ***p < 0.001 versus NTG or as indicated by brackets by
t test (B, D, and H) or Bonferroni-Holm test (E–G). Data are mean ± SEM. See
also Figure S6.
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considered clinically significant (Rockwood, 2004; Smith et al.,
2006). Our findings demonstrate an average Cohen’s d score
of 0.34 across three populations. This effect size exceeds that
of APOE ε4, the most robust known genetic modifier of cognition
in aging, calculated at 0.27 from longitudinal cognitive decline
(Deary et al., 2002) or at 0.13–0.25 from select baseline scores
in comparable aging individuals without dementia (Brown
et al., 2011). It also exceeds effect sizes of Food and Drug
Administration-approved treatments for AD, calculated between
0.15 and 0.28 (Rockwood, 2004; Smith et al., 2006). Determining
if the klotho effect translates into advantages in daily life or
greater reserve against neurodegenerative diseases is an impor-
tant objective.
Because our findings were replicated in three independent hu-
man cohorts in three geographic regions, it is likely that our infer-
ences are suitable at a population level, particularly because the
populations included community-dwelling individuals. However,
potential limitations in extrapolating our data worldwide include
that most participants were Caucasian and that our studies
were limited to the United States. Thus, it is possible that more
diverse genetic or environmental influences could alter or mask
the effect in other populations.
To our knowledge, the KL-VS variant has not been identified as
a significant modulator in genome-wide association studies
(GWASs) of human cognition in aging (De Jager et al., 2012;
Luciano et al., 2011; Seshadri et al., 2007), including in a study
of populations overlapping with the current study (De Jager
et al., 2012). However, our hypothesis-driven query of a popula-
tion previously studied by GWAS (De Jager et al., 2012) did, in
fact, reveal a significant association of KL-VS heterozygosity
with improved baseline cognition. Potential reasons for this
include (1) previous outcome measures focused on cognitive
decline (De Jager et al., 2012), which KL-VS did not prevent,
and (2) benefits of KL-VS are limited to the heterozygous state
and, thus,may bemissed by conventional GWASmethodologies
that assess additive effects of the minor allele.
Indeed, KL-VS homozygosity eliminates advantages in life-
span and health (Arking et al., 2002, 2005; Invidia et al., 2010;
Majumdar et al., 2010) and similarly eliminated cognitive advan-
tage in our discovery cohort (data not shown). The reasons for
the paradoxical dose effect of theminor allele are unknown. Pos-
sibilities include adverse effects of high klotho levels maintained
over decades in homozygous carriers or more complex dysregu-
lation of klotho expression by the variant. For example, it is
possible that the variant actually reduces klotho production,
resulting in abnormally low levels of klotho in homozygotes,
but causes a compensatory increase in expression of the wild-
type allele in heterozygotes. Additional studies are needed to
investigate these possibilities.
KL-VS homozygosity also decreased cognition in a previous
study by Deary et al. (2005), consistent with our findings. How-
ever, the previous study did not detect differences in cognitive
performance of KL-VS heterozygous individuals and non-
carriers. The reasons for this discrepancy are unknown. It is
worth noting, though, that we replicated our findings in three
independent cohorts and that the current study focused on tests
without maximum scores to increase the sensitivity of detecting
cognitive enhancement.1072 Cell Reports 7, 1065–1076, May 22, 2014 ª2014 The AuthorsKlotho-Mediated Cognitive Enhancement
Is Independent of Aging
In light of klotho’s role in aging, we were surprised that trans-
genic mice with global overexpression of klotho showed better
learning and memory than NTG controls at all ages examined,
including at 3 months, following entry into early adulthood.
Furthermore, KL-VS-associated increases in serum klotho levels
did not prevent aging-related cognitive decline in humans.
Instead, the KL-VS variant enhanced cognitive functions over a
wide age range, though there was a trend toward decreased
effects at the most advanced ages.
In our opinion, a plausible interpretation of these findings is
that the KL-VS variant, similar to global overexpression of klotho
in transgenicmice, modulates baseline cognition and that this ef-
fect diminisheswhen the age-associated decline in secreted klo-
tho levels (Duce et al., 2008; Semba et al., 2011) crosses a critical
threshold. Longitudinal studies over a broader age span are
needed to test this hypothesis. Although klotho elevation does
not slow down cognitive aging per se, its age-independent
cognition-enhancing effects could increase ‘‘cognitive reserve’’
and thereby augment one’s ability to counter adverse effects
of aging or related diseases, at least for a while.
Klotho and Mechanisms of Learning and Memory
In humans and mice, klotho effects were observed in cognitive
tests that interrogate functions of diverse networks that include,
but are not limited to, hippocampus and frontal cortex (Frankland
and Bontempi, 2005; Wang and Morris, 2010). Klotho enhanced
learning and memory in the water maze across several ages
(Table S1). We conducted mechanistic studies in young mice
because they are more readily available than older mice, yield
high-quality electrophysiological recordings, and allowed us to
address one of the most interesting findings of our studies—
that klotho enhances cognition even in the young life stage.
We focused on the hippocampus because of its well-character-
ized electrophysiological properties of learning and memory
circuits.
Klotho elevation increased neuronal FOS expression during
memory retrieval in thewater maze, as well as LTP and the decay
time of NMDAR currents. Collectively, these findings suggest a
causal role for NMDARs and their GluN2B subtype in klotho-
mediated cognitive enhancement.
The subunit composition of NMDARs dictates their functional
properties (Yashiro and Philpot, 2008). Because GluN2B-con-
taining NMDARs deactivate slower than GluN2A-containing
NMDARs (Wang et al., 2008), the increased decay time of
NMDAR currents in hippocampal slices from KL mice suggests
that klotho elevation augments the contribution of GluN2B-
containing NMDARs to NMDAR currents, a possibility that may
extend to other brain regions. Consistent with this hypothesis,
treatment of slices with the GluN2B-specific antagonist ifenpro-
dil preferentially reduced NMDAR current amplitudes and decay
constants in hippocampal slices fromKLmice.We conclude that
klotho elevation directly or indirectly increases the GluN2B
component of synaptic NMDAR activity, which in turn facilitates
induction of LTP (Foster et al., 2010; Yashiro and Philpot, 2008), a
potential substrate of learning and memory. In support of this
conclusion, blockade of GluN2B abolished klotho-mediated
increases in learning and memory. Because GluN2B is also
involved in long-term depression, homeostatic plasticity, and
metaplasticity (Brigman et al., 2010; Liu et al., 2004; Yang
et al., 2012), it will be interesting to determine if and how klotho
alters other forms of synaptic plasticity.
Although our initial screen of receptor subtype expression
revealed that klotho increased total hippocampal protein levels
of GluN2B, but not of other NMDAR or AMPAR subtypes, this
does not exclude the possibility that klotho modulates other
receptors in subcellular or submembrane compartments or
under disease conditions. Furthermore, cognition and its under-
lying substrates are complex. Therefore, other klotho-related
mechanisms may also contribute to enhanced cognition,
including regulation or signaling of other ion channels (Imura
et al., 2007), insulin (Chen et al., 2007; Kurosu et al., 2005), wnt
(Liu et al., 2007), or FGF23 (Urakawa et al., 2006) in neuronal or
nonneuronal cells. Klotho-mediated enrichment of GluN2B
could intersect with one or more of these pathways.
Klotho elevated total and synaptic GluN2B protein levels in a
subunit-specific manner without altering pre- and postsynaptic
markers. How klotho elevates total levels of GluN2B protein
and enriches GluN2B within synapses, directly or indirectly, re-
mains to be determined but may involve regulating translation,
posttranslational modification, recycling, or trafficking of the
subunit. It also remains to be determined whether the effects
of klotho elevation on GluN2B are mediated by the transmem-
brane or secreted form of klotho.
Our findings suggest that the KL-VS variant promotes cogni-
tion by increasing levels of secreted klotho. KL-VS carriers had
higher serum klotho than non-carriers—and in both groups,
higher klotho levels correlated or trended to correlate with better
cognitive function on tests such as semantic fluency, category
fluency, and modified trails (p = 0.04–0.17, linear regression
t tests, cohort 1; n = 153). Furthermore, elevating klotho levels
in another species, mice, also enhanced cognition. Nonetheless,
it is important to note that the KL-VS variant may also alter the
activities of klotho (Abraham et al., 2012; Arking et al., 2002;
Tucker Zhou et al., 2013). Additional studies are needed to further
explore the pleiotropic functions of this lifespan-extending and
cognition-enhancing factor. Strategies that increase the level
(Abraham et al., 2012; King et al., 2012) or activity of klotho or
simulate its functions may improve cognition at different life
stages and, possibly, even under pathological circumstances.
EXPERIMENTAL PROCEDURES
Cohorts
Several cohorts of humans and mice were utilized (Table S1).
Human Studies
Subjects were genotyped for the KL-VS variant. Cognitive data were collected
blinded to genotype. Neuropsychological testing (Figure S1) spanned multiple
cognitive domains (Table S4). Serum was analyzed for soluble a-klotho levels
by ELISA (Immuno-Biological Laboratories) (Yamazaki et al., 2010). Studies
were approved by committees on human research, and subjects provided
written informed consent before participating.
Mice, Cognition, and Behavior
NTG C57BL/6 mice were crossed with hemizygous KL transgenic mice (line
46) (Kuro-o et al., 1997), which express mouse klotho under the EF-1aCpromoter. All studies were conducted in a blinded manner on age-matched
and sex-balanced littermate offspring, unless indicated otherwise. Mice
were tested in the Morris water maze, Y maze, fear-conditioning apparatus,
elevated plus maze, and open field, as described by Cisse´ et al. (2011)
and Harris et al. (2010). All animal studies were approved by the Institutional
Animal Care and Use Committee of the University of California, San Francisco,
and conducted in compliance with National Institutes of Health (NIH)
guidelines.
Protein Analyses
Separation of synaptic membrane fractions (Goebel-Goody et al., 2009; Li
et al., 2011) was performed as described with minor modifications. Western
blot analyses and immunohistochemistry were performed as described (Palop
et al., 2003). Protein input, antibody dilutions, and other details are described
in Supplemental Experimental Procedures.
Electrophysiology
LTP was induced and measured from acute hippocampal slices using
methods as described by Cisse´ et al. (2011) with minor modifications.
AMPAR/NMDAR EPSC ratios and spontaneous EPSCs were recorded from
dentate granule cells as described in detail in the Supplemental Experimental
Procedures.
Statistical Analyses
Experimenters were blinded to the genotypes of humans and the genotypes
and treatment of mice. Statistical analyses were performed using GraphPad
Prism (5.0) for t tests, log rank tests, and repeated-measures ANOVA.
R (nlme package) was used for mixed-model ANOVAs, post hoc tests, princi-
ple component analysis, linear models, and power analyses.
See Supplemental Experimental Procedures for further details on all experi-
mental methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.03.076.
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